FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
This article was originally published in The Tan Sheet
Executive Summary
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
You may also be interested in...
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription
FDA Panel Opposes Lowering BMI Criteria For Obesity Clinical Trials
A majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee members recommended against lowering the body mass index for clinical trials involving weight-loss drugs
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).